- Dechra Pharmaceuticals on Tuesday completed the acquisition of the Brazilian-based Venco.

Venco had a large portfolio of vaccines and other food producing animal products, which it sold predominantly within Brazil.

It also had a small range of companion animal products vaccines and pharmaceuticals, which were sold mainly on the Brazilian market.

The acquisition of Venco would provide Dechra with a strategically significant presence within the rapidly growing Brazilian and South American markets.

Dechra would invest significantly over the next 2 to 3 years to develop the business and its presence in South America, and continue to develop the existing Venco pipeline and registrations, register relevant Dechra products and establish the Dechra brand in the region. 'We are delighted to complete on the Venco acquisition, enabling Dechra to establish a key new footprint in the rapidly expanding South American markets. We are pleased to welcome the Venco team to Dechra, to begin the integration process and our additional investment in this rapidly growing market,' said Ian Page, Dechra's Chief Executive Officer.

Story provided by